Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD – Research Report) and Pfizer (PFE – Research Report).
InMode (INMD)
Needham analyst Michael Matson maintained a Hold rating on InMode today. The company’s shares closed last Thursday at $17.35, close to its 52-week low of $16.82.
According to TipRanks.com, Matson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
InMode has an analyst consensus of Moderate Buy, with a price target consensus of $30.00.
See today’s best-performing stocks on TipRanks >>
Pfizer (PFE)
In a report released today, Elmar Kraus from DZ BANK AG maintained a Buy rating on Pfizer. The company’s shares closed last Thursday at $27.70, close to its 52-week low of $25.20.
According to TipRanks.com, Kraus is a 3-star analyst with an average return of
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $31.54, which is a 15.9% upside from current levels. In a report released today, Goldman Sachs also maintained a Buy rating on the stock with a $31.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INMD:
- INMD Earnings: Buybacks Aren’t Enough to Overcome Earnings Miss
- InMode Announces Q1 Results and Share Buyback
- InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;
- InMode responds to petition to USPTO filed by BTL Industries
- 3 Best Stocks to Buy Now, 4/12/2024, According to Top Analysts
